HKI-272 (neratinib)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for HKI-272 (neratinib), covering 2012-05-14 to 2024-05-22. Get the full timeline:
Most recent: Clinical Trial Update: HKI-272 for HER2-Positive Breast Cancer and Brain Metastases [Phase 2]